Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


EHA 25 European Perspectives Webinar: CLL

Related items

Congress news 22/06/2020

EHA 25 European Perspectives Webinar: Multiple Myeloma & CAR-T

In this webinar, Prof. Dr. John Gribben, Prof. Dr. Valentín Ortiz and PD Prof. Dr. Dr. Udo Holtick discuss three practice changing studies on Multiple Myeloma/CAR-T. Study 1 summarised by Prof. Dr. John Gribben IXAZOMIB VS PLACEBO AS POST-INDUCTION MAINTENANCE THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) NOT UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): PHASE 3 TOURMALINE-MM4 TRIAL Study 2 summarised by Prof. Dr. Valentín Ortiz IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121), A BCMA-TARGETED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: INITIAL KARMMA RESULTS Study 3 summarised by PD Prof. Dr. Dr. Udo Holtick LB2603 ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

EHA 25 European Perspectives Webinar: Lymphomas

In this webinar, Prof. Dr. Peter Borchmann and Dr. Robert Marcus discuss three practice changing studies on Lymphomas. Study 1 summarised by Prof. Dr. Peter Borchmann (S101) POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG and INTERIM ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (CARON A. JACOBSON) Study 2 summarised by Dr. Robert Marcus ROLE OF RADIOTHERAPY AND DOSE-DENSIFICATION OF R-CHOP IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A SUBGROUP ANALYSIS OF THE UNFOLDER TRIAL OF THE GERMAN LYMPHOMA ALLIANCE (GLA)   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

EHA 25 European Perspectives Webinar: AML

In this webinar, Prof. Dr. Nigel Russel, MD and Prof. Dr. Gert Ossenkoppele discuss two practice changing studies on AML. Study 1 summarised by Prof. Dr. Nigel Russell MD (S144) THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN AML PATIENTS: PHASE 1B RESULTS Study 2 summarised by Prof. Dr. Gert Ossenkoppele (LB2601) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

ASCO Discussion Round III: Highlights from a European Perspective

In this third live discussion round, experts from Switzerland and Germany discuss practice-changing studies in the fields of GU, Immunoncology and Hematology with the ASCO2020 original authors.  The following authors are presenting their studies:  Dr. Thierry André Sorbonne University and Saint-Antoine Hospital, Paris, France Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study   Prof. Dr. Shaji Kumar Mayo Clinic, Rochester, MN, USA Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.   Dr. Landon Carter Brown Duke Cancer Institute, Durham, North Carolina, USA Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.   Dr. Jesus G. Berdeja Sarah Cannon Research Institute, Nashville, TN, USA Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.   Prof. Dr. Thomas Powles Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, London, UK Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

Congress news 22/06/2020

European clinicians share their local perspectives on practice changing studies from EHA25 Virtual

MEDtalks in association with The European Hematology Association has launched a series of four webinars, covering some of the most important practice changing studies presented at EHA25 Virtual. We invited leading European clinicians and study authors from the UK, Germany, Spain, the Netherlands and Switzerland to discuss the relevance of these studies for their local clinical practice. The webinar series was divided into the following topics: Multiple Myeloma & CAR-T, Lymphoma, CLL and AML. You can watch the webinars below: Multiple myeloma & CAR-T Webinar Lymphomas Webinar CLL Webinar AML Webinar All webinars are moderated by PD Dr. med. Jens Ulrich Rüffer. The webinars are independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

AML, MDS, MPN - Dr. Goede // Highlights EHA25

In this presentation, PD Dr. Goede from the Cantonal Hospital in Winterthur presents his Highlights for the topic " AML, MDS, MPN " from the EHA25 virtual Meeting. TOPICS AML LB2601: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A Courtney DiNardo et al.   S139: ENASIDENIB PLUS AZACITIDINE SIGNIFICANTLY IMPROVES COMPLETE REMISSION AND OVERALL RESPONSE RATES VERSUS AZACITIDINE MONOTHERAPY IN MUTANT-IDH2 NEWLY DIAGNOSED AML. Courtney DiNardo et al. S144: THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINDE WITH AZACITIDINE IS WELL TOLERATED AND EFFECTIVE IN AML PATIENTS: PHASE 1B RESULTS Naval Daver et al.   MDS S183: TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE IN HEAVILY TRANSFUSED NODN-DEL5Q LOWER RISK MDS RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS Uwe Platzbecker et al.,   MPN  S217: RUXOLITINIB DISCONTINUATION SYNDROME: INCIDENCE, RISK FACTORS AND MANAGEMENT IN 242 PATIENTS WITH MYELOFIBROSIS Francesca Palandri et al.

Congress news 22/06/2020

Aggressive Lymphoma – Professor Renner // Highlights EHA25

In this presentation, Prof. Renner from the Oncology Center in Zurich presents his Highlights for the topic "Aggressive Lymphoma (incl. Hodgkin + MCL)" from the EHA25 virtual Meeting. TOPICS S101: POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG Peter Borchmann LB2600: PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PEMBROLIZUMAB (PEMBRO) VERSUS BRENTUXIMAB VEDOTIN (BV) FOR TREATMENT OF RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-204 Pier Luigi Zinzani S230: ROLE OF RADIOTHERAPY AND DOSE-DENSIFICATION OF R-CHOP IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A SUBGROUP ANALYSIS OF THE UNFOLDER TRIAL OF THE GERMAN LYMPHOMA ALLIANCE (GLA). Gerhard Held S235: OUTCOME OF LIMITED STAGE PERIPHERAL T-CELL LYMPHOMA AFTER CHOP(-LIKE) THERAPY: A POPULATION BASED STUDY OF 251 PATIENTS FROM THE NORDIC LYMPHOMA EPIDEMIOLOGY GROUP Ahmed Ludvigsen Al-Mashhadi S236: HIGH DOSE METHOTREXATE CNS PROPHYLAXIS IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A MULTICENTRE ANALYSIS OF TOXICITY AND IMPACT ON R-CHOP DELIVERY Matthew Wilson S243: OUTCOME OF HIGH-GRADE LYMPHOMA PATIENTS TREATED WITH CD19 CAR-T – UPDATED REAL-WORLD EXPERIENCE IN THE UK Andrea Kuhnl